Of participants, 84.3% found pharmacogenomics relevant to their current practice
More than two-thirds (65.7%) did not order nor recommend a pharmacogenomic test in the past year
pharmacogenomic testing was understood mainly for assessment of the variability of genes affecting drug disposition, metabolism and drug transport leading to individual responses to drugs
Pre-emptive, prospective, genotyping to make individualised drug therapy feasible is seen to contribute to personalised medicine
assumed to improve drug efficacy and safety
Potential benefits of pharmacogenomics (PGx) have been defined such as predicting intended response to medication by more accurate dosing, avoiding adverse drug reactions and therefore enhancing drug safety and reducing health care cost
survey among Dutch pharmacists revealed 14.7% recent users of PGx diagnostics [27], whereas in our cohort, the percentage was with 34.3% higher.